Rivopharm is a Swiss company located near Lugano in the canton of Ticino. Its core business is the development and manufacture of generic pharmaceutical products that meet the same strict quality standards of those of the originator. With a strong regulatory department, an extremely motivated and efficient research and development team and a brand new factory, Rivopharm provides a customer-oriented approach towards product development, registration and production delivered with a well-deserved reputation for Swiss efficiency, high quality and reliability.
In addition to the development and production of generic products, the management’s philosophy is to provide innovative solutions in the area of new product developent to add value to the business of its customers and in this regard Rivopharm has expanded its product development capabilities to capitalize on the latest advances in product formulation and drug delivery technology.
Rivopharm milestones achieved in recent years include:
2018
Start of direct marketing in Austria, Hungary and Poland
2017
Acquisition of Sanoswiss, the new affiliate of Rivopharm Group in Baltics
Launch of two generic products in US
Acquisition of a basket of 77 molecules from Teva
2016: Acquisition of Holsten Pharma, the new German affiliate of Rivopharm Group; In early 2016 Rivopharm SA obtained ANDA's approval for 2 products
2015: First company to launch generic Racecadotril capsules.
2014: Successfully passed the US-FDA inspection with no 483’s
2013: First branch office opens in the UK for the direct marketing of its product in this market;
2013: Successful conclusion of development of Racecadotril 100 mg capsules;
2012: First to successfully complete the registration dossier for Lacidipine tablets 6 mg;
2011: First to launch generic Nicorandil tablets in EU market
2010: First ever registration of Nicorandil tablets as generic product in some European countries.